Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Discovery of a Novel P2X2/3 Allosteric Antagonist as an Efficient Bitter Taste Blocker.
Journal: Journal of medicinal chemistry
Published: April 10, 2026
Improving Mental Health and Well-Being Through the Paradym App: Quantitative Study of Real-World Data.
Journal: JMIR formative research
Published: October 26, 2024
Expanding the phenotype of UPF3B-related disorder: Case reports and literature review.
Journal: American journal of medical genetics. Part A
Published: October 16, 2023
Stereospecific antiseizure activity in mouse and rat epilepsy models by a pyridinium inhibitor of TNFα/NFκB signaling.
Journal: European journal of medicinal chemistry reports
Published: August 25, 2022
Mechanism of glycogen synthase inactivation and interaction with glycogenin.
Journal: Nature communications
Published: March 24, 2022
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours.
Journal: British journal of cancer
Published: November 05, 2020
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
Journal: British journal of cancer
Published: November 05, 2020
The Impact of COVID-19 on Epilepsy Care: A Survey of the American Epilepsy Society Membership.
Journal: Epilepsy currents
Published: September 18, 2020
Trends in oral anticoagulant co-prescription with antiepileptic drugs among adults with epilepsy, 2010-2018.
Journal: Epilepsy & behavior : E&B
Published: August 29, 2020
Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.
Journal: Journal of medicinal chemistry
Published: May 11, 2019
Last Updated: 09/26/2026